Verastem, Inc. , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of a Phase 2 trial of defactinib , a potent inhibitor of focal adhesion kinase , in KRAS-mutated non-small cell lung cancer .
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130926005832&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130926005832&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment